Roche's antibody med MabThera (Rituxan) just aced two trials aimed at expanding uses for the drug: one that pitted MabThera against rheumatoid arthritis and another that used it against adult leukemia. One analyst called the drug "a pipeline in a molecule." Report [1]
Links:
[1] http://www.marketwatch.com/news/story/roches-antibody-mabthera-sails-through/story.aspx?guid=%7BE8A15113-B259-47B1-90E6-A38CEC843903%7D